Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exemestane vs TC in HR+ Breast Cancer (RS 11-24)
NCT00941330Phase 2Completed
- Sponsor
- Emory University
- Start
- Jul 2009
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by Emory University. Primary endpoint: Pathologic Complete Response. Started Jul 2009; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00941330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941330.